BioSpace News Archive

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces encouraging final data from its Phase I INSIGHT-004 study.

Travere Therapeutics (NASDAQ: TVTX) today announced presentations including nonclinical data examining the renal protective effects of sparsentan, a high affinity antagonist of both endothelin type A (ETA) and angiotensin II type 1 (AT1) receptors, in focal segmental glomerulosclerosis (FSGS) mouse models, at the 58th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress.

DENTSPLY SIRONA Inc., announced that it has acquired substantially all of the assets of Propel Orthodontics in an all-cash deal for $131 million.

PathAI, today announced that new data highlighting the application of its ML-based PathR algorithm to clinical trials as an aid to pathologists will be presented in the American Society of Clinical Oncology (ASCO) Virtual Scientific Program 2021, held from June 4-8, 2021.

SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented initial results from its ongoing Phase 1 clinical trial

Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced initial results from an ongoing Phase 1 clinical trial of its oncolytic virus, CAN-3110, in patients with high-grade glioma (HGG) that has recurred after initial treatment.

Peijia Medical Limited signed a memorandum of strategic cooperation with China Resources Pharmaceutical Commercial Group Medical Devices Co., Ltd. on June 2 . Going forward, the two parties will collaborate intensively on the commercialization of TAVR products, ultimately providing more Chinese medical staff and patients with better quality goods.

Data from oral docetaxel phase I pharmacokinetic study shows oral administration can achieve exposure comparable to IV docetaxel

Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today summarized in a poster presentation preliminary data from the ongoing Phase 1/2 trial of CPI-0209

Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that a poster presentation discussing preliminary data from the Phase 1/2 clinical trial of BDC-1001,